

September 29, 2026  
JCR Pharmaceuticals Co., Ltd.

## Notice of Organizational and Personnel Changes

**Hyogo, Japan – September 29, 2026 – [JCR Pharmaceuticals Co., Ltd.](#)** (TSE 4552; “JCR”) today announced the following organizational and personnel changes.

1. Personnel Change (As of October 1, 2026)

| Name          | New Title                                        | Current Title                       |
|---------------|--------------------------------------------------|-------------------------------------|
| Yuichi Kimura | Director, Kanto Sales Department, Sales Division | Senior Professional, Sales Division |

2. Organizational and Personnel Change (As of November 1, 2026)

(1) Organizational Change

In response to the company's growth, the increasing complexity of the business environment, and system transformation, the Accounting Department will be transferred under the Administration Division to further promote business transformation and productivity improvements across administrative operations.

(2) Personnel Change

| Name          | New Title                                                                                                                                             | Current Title                                                |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|
| Tadahiro Hama | Director, Accounting Department, Administration Division and Group Manager, Business Innovation Group, Accounting Department, Administration Division | Director, Accounting Department, Corporate Strategy Division |

### About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: <https://jcrpharm.com/>

### Contact:

Investors & Media:  
JCR Pharmaceuticals Co., Ltd.  
Corporate Communications  
[ir-info@jp.jcrpharm.com](mailto:ir-info@jp.jcrpharm.com)

###